WE ARE

MAKING
ALZHEIMER'S
PREVENTABLE

The world's first integrated home platform combining AI-powered early detection with breakthrough non-invasive brain therapy that treats and prevents Alzheimer's disease.

Amygo non-invasive brain therapy device for mild to moderateAlzheimer's treatment and prevention

Prototype worn by Director of Engineering Bruce Kong B.A.Sc

THE CRISIS

ALZHEIMER'S IS
GROWING FAST

ALZHEIMER'S
DISEASE
$2.8T PER YEAR
ON DEMENTIA TREATMENT
Global Coalition on Aging
(Globally) 1

300% INCREASE BY 2050
IN DEMENTIA CASES

World Health Organization (WHO)
(Canada) 2

Over 400 million people worldwide are affected by dementia, with cases expected to triple by 2050. Despite this, up to 75% of cases remain undiagnosed until symptoms become severe.

Cognitive Test Scores

We are currently in the clinical phase of our product development journey, with a pilot study of 8 people showing a reversal of mild dementia symptoms within just two weeks of treatment. We are currently raising funds to complete larger clinical trials.

Amygo Software Mockup
OUR SOLUTION

BREAKTHROUGH
TECHNOLOGY

Revolutionary dual-platform combining a non-invasive brain therapy with AI-powered early detection for home use.

🧠

Non-invasive Medical Device

The Amygo is a revolutionary device which undoes the damage of dementia by breaking apart the proteins in the brain that cause the disease and by stimulating neurogenesis.

🤖

AI-Powered Diagnostic Sofware

Out first-of-its-kind diagnostic software allows for clinician-level screening all from the discretion of your own home. 75% of people with dementia go undiagnosed.3 Catching it before severe symptoms appear allows for better interventions.

🏠

Home-Based Convenience

Lightweight device attaches to baseball cap for seamless daily treatment

📱

Continuous Monitoring

Our software allows for daily symptom tracking, giving peace of mind to caretakers. Used with our device, the evidence of recovery is in your hands.

Our latest prototype of our non-invasive medical device

COMPETITIVE ADVANTAGE

WHY AMYGO
WINS

Compared to existing solutions, Amygo delivers superior outcomes with fewer risks.

Non-invasive
Side Effects
Efficacy
At-home
Preventative
Amygo
Yes
None
STRONG
Yes
Yes
Ultrasound
No
High
Moderate
No
No
tDCS
No
Medium
Weak
No in Canada, Yes in EU
No
TMS
Yes
Medium
Weak
No
No

OUR PROGRESS

Take a look at our latest Stage of Product report for more information on our progress and how we are revolutionizing Alzheimer's disease treatment and prevention.

MARKET OPPORTUNITY

MASSIVE
ADDRESSABLE
MARKET

2.8T globally is spent annually on dementia treatment. 1

This figure is expected to triple by 2050, along with the amount of patients with dementia. 2

416.5M PATIENTS
TAM

Total Addressable Market
(Global) 4

46.7M
SAM
Serviceable Addressable Market
(North America) 5

3.46M
SOM

Serviceable Obtainable Market
(Canada) 6 4

OUR VISION

GLOBAL
IMPACT

We envision a world where Alzheimer's disease no longer exists, and Amygo devices are a regular part of informed self-care as common as home blood pressure monitors.

GET IN TOUCH

CONTACT US

Have questions? We'd love to hear from you.

contact@amygo.ca

Due to technical difficulties, any messages sent before July 9th, 2026 to this address were not received.

Please fill out the form above if you sent a message prior to this date.


Amygo Medical Systems
Unit 206 – 9639 137 A St.
Surrey, BC V3T 0M1